Realizing the CAR T Potential in Myositis & Beyond
Cabaletta Bio is a clinical-stage biotechnology company focused on developing T cell therapies with potential to provide durable, perhaps curative, treatment for patients with autoimmune diseases. CABA-201, a CD19-CAR T cell therapy, is being evaluated in the RESET™ Phase 1/2 trials across several autoimmune diseases, including adult and juvenile myositis.
Tania Gonzalez Rivera, M.D., discusses the application of CAR-T cell therapy in treating myositis and delves into the mechanism of CAR-T therapy, its successes, challenges, and future prospects in revolutionizing autoimmune disease treatment.
Dr. Gonzalez is a renowned physician and executive leader in the biotechnology industry. She currently serves as the Vice President of Medical Affairs at Cabaletta Bio, a company dedicated to developing novel therapies for autoimmune diseases. Dr. Gonzalez completed her Doctor of Medicine and Residency at the University of Puerto Rico School of Medicine and her Rheumatology Fellowship at the University of Michigan Medical School.
Her research and clinical expertise include autoimmune diseases, particularly in the areas of rheumatology and dermatology. She has published numerous papers in peer-reviewed journals on topics such as psoriasis, and lupus, and presented research findings at major scientific conferences, including the American Academy of Dermatology and the American College of Rheumatology.
